Good takeover target

Discussion in 'Lexicon Pharmaceuticals' started by Anonymous, Apr 9, 2015 at 6:06 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    A few of the larger biotech's are watching this little gem
     

  2. Anonymous

    Anonymous Guest

    Regeneron paid a visit two weeks ago
     
  3. Anonymous

    Anonymous Guest

    Cash for licensing deals will be in the future
     
  4. Anonymous

    Anonymous Guest

    ask to see legacy Organon audit
     
  5. Anonymous

    Anonymous Guest

    all interested parties meet in 10-Forward
     
  6. anonymous

    anonymous Guest

    the only thing they have to offer is hype
     
  7. anonymous

    anonymous Guest

    show me the money! hype all hype
    where's the mouse to human megablockbuster
     
  8. anonymous

    anonymous Guest

    The bottom line, all of us TBMs are all in big pharma hell here. We are all sticking around to see what the Sota data looks like in July. If it's good, we try to stick around for someone to save us with a buyout, if it's bad or average, this place will be a ghost town. That is real talk...
     
  9. anonymous

    anonymous Guest

    Preach on! Couldn't say it any better! Cheers to July data for Sanofi to save us all or "it's on to the next one"! Jay Z style!!
     
  10. anonymous

    anonymous Guest

    Any talk about rolling over the contract reps?
     
  11. anonymous

    anonymous Guest

    Lexicon reps leaving already, need to backfill them first.
     
  12. anonymous

    anonymous Guest

    Ipsen or Sanofi needs to save this place quick!! Never seen so much big pharma in my life.
     
  13. anonymous

    anonymous Guest

    Organon audit- amazing what lack of notebooks will do (if I recall correctly)
    with the SGLT1/2 from selective to dual acting in a single day- look at the wiki page history
    LXRX doesn't lie- just doesn't understand truth
     
  14. anonymous

    anonymous Guest

    Think positive. Sanofi bought in because sota data in PIIs were excellent. These guys are not absolutely stupid there to invest hundreds of millions in current PIIIs. Takeover will come shortly before data are disclosed, as usual....Right, Lexicon reps will not be needed there ...
     
  15. anonymous

    anonymous Guest

    where are the MULTIPLE drugs promised GENENOME5000
    long live the hype.......

    btw SGLT1 accounts for 10% of total reuptake...... from selective to dual in one easy WIKI change

    gotta love the company